For the treatment of RA, peficitinib is an oral JAK inhibitor that targets JAK family enzymes (JAK1, JAK2, JAK3, TYK2) and blocks the signal transduction of various cytokines, including GM-CSF [161]. This evidence concerns the gene CSF2 and rheumatoid arthritis.